Regulation of melanoma initiating cells by Hedgehog signaling and SOX2 by Roberta Santini et al.
ORAL PRESENTATION Open Access
Regulation of melanoma initiating cells by
Hedgehog signaling and SOX2
Roberta Santini1, Silvia Pandolfi1, Valentina Montagnani1, Silvia Pietrobono1, Nicola Pimpinelli2,
Lorenzo Borgognoni3, Barbara Stecca1*
From Melanoma Bridge meeting 2013
Naples, Italy. 5-8 December 2013
Background
Recent reports suggest that within the heterogeneous popu-
lation that constitutes a melanoma, certain cell types exhi-
bit molecular and functional features similar to stem cells.
These melanoma-initiating cells (MICs) have the ability of
unlimited self-renewal, multilineage differentiation and the
potential to initiate and maintain tumor growth [1].
Furthermore, MICs are believed to confer chemoresistance
to conventional chemotherapeutic agents and newly devel-
oped molecularly-targeted drugs [2,3]. Therefore, defining
the molecular and biochemical pathways that support
MICs is of critical importance for the development of more
efficient targeted therapies. We have previously shown that
the HEDGEHOG (HH) signaling is required for melanoma
growth [4] and for survival and expansion of MICs [5].
Here we investigate the mechanism by which inhibition of
the HH signaling leads to a decrease of MIC stemness,
addressing the role of the transcription factor SOX2.
Materials and methods
MICs were enriched by Fluorescence Activated Cell Sort-
ing using the metabolic marker Aldehyde Dehydrogenase
(ALDH) and by establishing melanoma spheres in non-
adherent culture conditions from 20 human melanomas.
Expression of SOX2 and of HH pathway components was
determined by real time PCR and Western blot analysis.
Modulation of the HH signaling was performed by stable
expression of lentiviral vectors encoding short-interference
RNAs specific for SMO or GLI1 (to inhibit HH), and
PTCH1 (to activate HH). Functional analysis of SOX2 was
performed by stable overexpression and silencing using
lentiviral vectors.
Results
We find that the HH signaling regulates the expression
of SOX2 and the downstream effectors of the HH sig-
naling, the transcription factors GLI1 and GLI2, bind to
SOX2 promoter in melanoma cells. Functionally, we
show that SOX2 is required for HH-induced melanoma
cell growth and MIC self-renewal. We present evidence
that SOX2 is highly expressed in a population enriched
for cancer stem cells in patient-derived melanomas.
Knock-down of SOX2 sharply decreases self-renewal of
melanoma spheres and of ALDHhigh melanoma stem
cells. Consistently, ectopic expression of SOX2 in mela-
noma cells is sufficient to enhance stemness in vitro.
SOX2 silencing also inhibits cell growth and induces
apoptosis in melanoma cells. Most importantly, deple-
tion of SOX2 drastically impairs tumorigenicity of
ALDHhigh MICs in orthotopic xenografts.
Conclusion
Our data identify SOX2 as a novel mediator of the HH
signaling in melanoma cells and indicate that SOX2 is a
critical factor for the survival of MICs. These findings
could provide the basis for novel therapeutic strategies
based on the inhibition of SOX2 for the treatment of
human melanomas.
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